Transparency is a critical part of our ongoing collaboration with key stakeholders, helping to build a community of trust and respect with our employees, patients, healthcare professionals, industry peers, stockholders and the overall community.

Biogen is committed to transparency and disclosure of environmental, social and governance (ESG) issues that are material to the business and of interest to our stakeholders.


ESG Materiality Assessment Process

As part of the review of our global Corporate Responsibility strategy, in 2021, we conducted a materiality assessment, engaging a broad range of stakeholders, adopting a new approach to questions and a deeper analysis to identify and prioritize (ESG) issues at the intersection of stakeholder and company concern.

Read the detailed results of our materiality assessment in our Reporting section.


Task Force on Climate-Related Financial Disclosures Statement

Biogen supports the Task Force on Climate-related Financial Disclosures (TCFD). Through our 2021 TCFD statement, we provide our second disclosure aligned with TCFD recommendations. 

Read our TCFD Statement.


Safe Harbor

Our 2021 Year in Review contains forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Read our safe harbor statement


Additional Resources:

Report Archive


Quick Links


Read the Data and Indices